Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. - Wikidata - awgldk - TriplyDB

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

http://www.wikidata.org/entity/Q37724614

about

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.Association of rs2254638 Polymorphism With Clopidogrel Response in Chinese Patients With Coronary Artery Disease Impact of Obstructive Sleep Apnea on Platelet Function Profiles in Patients With Acute Coronary Syndrome Taking Dual Antiplatelet Therapy

P2860

Q55444892-3006D12B-24D1-4E24-A7B5-2DF537AE39A6 Q57072916-7A7FE120-A567-4084-86F6-1E9C840B31FD Q58129990-22E6088E-0E04-4EE8-A8CB-8180D87CB69B

P2860

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

http://www.wikidata.org/entity/Q37724614

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 March 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

@en

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

@nl

type

label

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

@en

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

@nl

prefLabel

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

@en

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

@nl

P1433

Q37724614-FC153726-2AB2-471C-ADAA-5C4CAC98E55B

P1476

Q37724614-F334B60A-0C5B-4081-9F76-99658FFE97BF

P2093

Q37724614-3DBA6E03-73BA-4C3A-8775-FD364548A21D

Q37724614-7B1A17CB-B43D-4E4D-A3B6-2C5F8137EC6B

Q37724614-D48215BC-48B9-4BB6-9A6C-175D9632B12A

Q37724614-E451B4ED-EB93-4582-B5C3-1EF862477DE0

P275

Q37724614-6E7956A3-B6A9-4CF9-A581-A14246CE6706

P2860

Q37724614-012B9D42-EE3E-4A07-9B57-C1B18E43C0B4

Q37724614-020838C4-5350-440C-A1B5-4370A7FF72E3

Q37724614-0331709D-18D0-4A01-A539-21BE6A60D105

Q37724614-053E85CC-16F5-4F6F-B080-18A57549B719

Q37724614-0792254B-2140-4A1E-A779-ADEF40854DD9

Q37724614-0EE02026-1776-4755-9FB2-A888292A6794

Q37724614-10252B6E-11A7-4A04-9E20-2BF50EDA6715

Q37724614-105F2E23-2E8C-4A00-A109-5D1F5857EBFD

Q37724614-15EE57D7-5770-4B8E-93ED-14B66C785D2B

Q37724614-176262A2-0C71-49F0-956F-F75FECAF2750

P31

Q37724614-CFBEC3C3-68E6-4752-A64D-9EBFBD0EA564

Q37724614-D785959E-FDA6-4263-AE4D-70B3BEAD8981

P356

Q37724614-5EB23483-2838-4769-A08E-9022B82E5D32

P433

Q37724614-2C9AD264-CF7F-474B-8BD1-67415F612D9A

P478

Q37724614-57CCBF0F-560A-4C06-9A7A-9B967F4ED63A

P577

Q37724614-2131E938-B860-4196-A980-AAA18F452AB5

P698

Q37724614-207C3A52-7CE4-41A7-A0C1-24F3FE7C6FCF

P921

Q37724614-5C75F799-E768-43DF-A23B-5474AC5C4D1A

Q37724614-9472D6F3-A3F8-453A-AB94-ACE705D557CC

Q37724614-EC3B9F37-CC12-48E6-AE8B-A69A52C3E416

P932

Q37724614-B0FA0E79-6332-4C78-A00A-C90A161300C7

P356

P1433

International Journal of Environmental Research and Public Health

P1476

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

@en

P2093

Jie Tang

http://www.w3.org/2001/XMLSchema#string

Mu-Peng Li

http://www.w3.org/2001/XMLSchema#string

Xiao-Ping Chen

http://www.w3.org/2001/XMLSchema#string

Yan-Jiao Zhang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors : functional and biochemical aspects

VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA

Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

Role of microRNAs in plant and animal development

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial

Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome

Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease

P31

scholarly article

P356

10.3390/IJERPH14030301

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28335443

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

membrane proteins

P932

5369137

http://www.w3.org/2001/XMLSchema#string